Literature DB >> 16182109

Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

Brigitte Sondermeijer1, Andrew Kompa, Paul Komesaroff, Henry Krum.   

Abstract

BACKGROUND: Plasma levels of urotensin-II (U-II) have been found to be elevated in patients with essential hypertension. However, the consequence of activation of the U-II system have not been previously determined in these patients. We therefore compared the effect of exogenous U-II administration on vascular tone in hypertensive patients (n = 13) and normotensive subjects (n = 14).
METHODS: The effect of U-II on vascular tone was determined in the forearm skin microcirculation using iontophoresis to administer the drug and laser Doppler velocimetry to measure microvascular response.
RESULTS: The U-II administration was associated with a dose-dependent vasodilator response from baseline in normotensive subjects (U-II 1 x 10(-12) mol/L, 609 +/- 164; U-II 1 x 10(-9) mol/L, 839 +/- 216; U-II, 1 x 10(-7) mol/L, 1249 +/- 228 arbitrary flux units; P < .0005). A dose-dependent vasoconstrictor response was observed in hypertensive patients compared to baseline (U-II 1 x 10(-12) mol/L, 60 +/- 212; U-II 1 x 10(-9) mol/L, -288 +/- 172; U-II, 1 x 10(-7) mol/L, -607 +/- 165 arbitrary flux units; P < .005). Differences in flow between the two groups were significant at the 1 x 10(-9) mol/L and 1 x 10(-7) mol/L dose levels (P < .001). In contrast, there was no significant difference in flux between baseline and U-II in either group (or between groups) when the opposite polarity was applied.
CONCLUSIONS: The demonstration of opposing effects of exogenous U-II in patients with hypertension and normal subjects suggests that U-II may be contributory to the increased vascular tone of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182109     DOI: 10.1016/j.amjhyper.2005.03.748

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  17 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

2.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

3.  Does cigarette smoking increase plasma urotensin II concentrations?

Authors:  S J Gold; J P Thompson; J P Williams; E E F Helm; J Sadler; W Song; L L Ng; D G Lambert
Journal:  Eur J Clin Pharmacol       Date:  2007-01-25       Impact factor: 2.953

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 5.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

6.  The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.

Authors:  Joseph Cheriyan; Timothy J Burton; Timothy J Bradley; Sharon M L Wallace; Kaisa M Mäki-Petäjä; Isla S Mackenzie; Carmel M McEniery; John Brown; Ian B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

7.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

8.  Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

Review 9.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

10.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.